BACKGROUND: Prostaglandin E2 (PGE2) is a pathogenesis of inflammatory diseases; PGE2 plays a key role in association of anti-inflammation and immune suppression. EP4, which is a PGE2 receptor, is known to suppress the production of inflammatory cytokines and chemokines in vitro. Although it has been reported that EP4 agonists prolonged cardiac allograft survival, little has been elucidated the immunologic mechanism. METHODS: We injected a selective EP4 agonist (EP4RAG) into recipient mice with heterotopic cardiac transplantation. RESULTS: EP4RAG significantly prolonged the graft survival compared with the vehicle-treated group. Although the vehicle-treated group showed severe myocardial cell infiltration, the EP4RAG-treated group attenuated the development on day 7. EP4RAG suppressed various proinflammatory factors such as cytokines, chemokines, adhesion molecules, and nuclear factor-kappaB (NF-kappaB) compared with the vehicle-treated group. We also demonstrated that EP4RAG suppressed the activation of macrophages, but it did not affect to T lymphocytes in vitro. EP4RAG inhibited the activation of NF-kappaB compared with the control group. CONCLUSION: Pharmacological selective EP4 activation suppressed the production of proinflammatory factors by inhibition of NF-kappaB activity in cardiac transplantation.
BACKGROUND:Prostaglandin E2 (PGE2) is a pathogenesis of inflammatory diseases; PGE2 plays a key role in association of anti-inflammation and immune suppression. EP4, which is a PGE2 receptor, is known to suppress the production of inflammatory cytokines and chemokines in vitro. Although it has been reported that EP4 agonists prolonged cardiac allograft survival, little has been elucidated the immunologic mechanism. METHODS: We injected a selective EP4 agonist (EP4RAG) into recipient mice with heterotopic cardiac transplantation. RESULTS: EP4RAG significantly prolonged the graft survival compared with the vehicle-treated group. Although the vehicle-treated group showed severe myocardial cell infiltration, the EP4RAG-treated group attenuated the development on day 7. EP4RAG suppressed various proinflammatory factors such as cytokines, chemokines, adhesion molecules, and nuclear factor-kappaB (NF-kappaB) compared with the vehicle-treated group. We also demonstrated that EP4RAG suppressed the activation of macrophages, but it did not affect to T lymphocytes in vitro. EP4RAG inhibited the activation of NF-kappaB compared with the control group. CONCLUSION: Pharmacological selective EP4 activation suppressed the production of proinflammatory factors by inhibition of NF-kappaB activity in cardiac transplantation.
Authors: Eva H C Tang; Koichi Shimizu; Thomas Christen; Viviane Z Rocha; Eugenia Shvartz; Yevgenia Tesmenitsky; Galina Sukhova; Guo-Ping Shi; Peter Libby Journal: Cardiovasc Res Date: 2010-08-24 Impact factor: 10.787
Authors: Eva H C Tang; Yin Cai; Chi Kin Wong; Viviane Z Rocha; Galina K Sukhova; Koichi Shimizu; Ge Xuan; Paul M Vanhoutte; Peter Libby; Aimin Xu Journal: J Lipid Res Date: 2014-12-15 Impact factor: 5.922